SMI-4a (TCS PIM-1 4a) is a potent Pim1 inhibitor with an IC50 of 17 nM and is moderately effective against Pim-2, with no significant inhibition of other silk/threonine or tyrosine kinases.

 

Brand: BCM

 

Target: Pim

 

Signaling Pathways: Chromatin/Epigenetic; JAK/STAT signaling

 

In Vitro: One hour after oral administration of SMI-4a, p70S6K phosphorylation was reduced compared to the tumors of control mice, while total p70S6K expression was unchanged. SMI-4a treated with 60 mg/kg twice daily significantly reduced tumor size and was well tolerated.

 

pKa: 7.38±0.20(Predicted)

 

Solubility: Soluble in DMSO; Soluble in Ethanol. Insoluble in Water.

 

GHS: GHS07

 

Isomeric SMILES: C1=CC(=CC(=C1)C(F)(F)F)/C=C\2/C(=O)NC(=O)S2  

 

InChIKey: NGJLOFCOEOHFKQ-YVMONPNESA-N  

 

InChI: InChI=1S/C11H6F3NO2S/c12-11(13,14)7-3-1-2-6(4-7)5-8-9(16)15-10(17)18-8/h1-5H,(H,15,16,17)/b8-5-  

 

Attribute
[Chem Name]	(5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione
[Synonym]	SMI-4a; TCS PIM-1 4a
[CAS No.]	438190-29-5
[EINECS]	200-256-5
[MDL No.]	MFCD01152003
[Formula]	C11H6F3NO2S
[Molecular]	273.23
[Form]	White to beige powder
[Storage]	Sealed in dry, 2-8°C

Goods Tag